Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 9 | 2026 | 713 | 0.970 |
Why?
|
| Lung Neoplasms | 7 | 2026 | 702 | 0.830 |
Why?
|
| Kidney Neoplasms | 5 | 2023 | 173 | 0.690 |
Why?
|
| Urethral Stricture | 4 | 2023 | 70 | 0.620 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2023 | 114 | 0.590 |
Why?
|
| Lichen Sclerosus et Atrophicus | 4 | 2023 | 20 | 0.560 |
Why?
|
| Bariatric Surgery | 2 | 2026 | 65 | 0.370 |
Why?
|
| Obesity, Morbid | 2 | 2026 | 93 | 0.360 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 184 | 0.340 |
Why?
|
| Gene Expression Profiling | 8 | 2026 | 794 | 0.340 |
Why?
|
| Gene Expression | 2 | 2026 | 852 | 0.320 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 364 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2026 | 583 | 0.260 |
Why?
|
| Neoplasm Staging | 6 | 2026 | 544 | 0.240 |
Why?
|
| Penile Induration | 1 | 2026 | 6 | 0.240 |
Why?
|
| Weight Loss | 2 | 2026 | 276 | 0.230 |
Why?
|
| Penis | 1 | 2026 | 37 | 0.230 |
Why?
|
| Sequence Analysis, RNA | 2 | 2026 | 180 | 0.210 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2021 | 51 | 0.190 |
Why?
|
| Urethra | 2 | 2021 | 77 | 0.190 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 108 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 4 | 2026 | 287 | 0.170 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 5 | 0.170 |
Why?
|
| Biomarkers, Tumor | 2 | 2026 | 524 | 0.170 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2021 | 8 | 0.170 |
Why?
|
| Middle Aged | 12 | 2026 | 18273 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 261 | 0.160 |
Why?
|
| Virus Internalization | 1 | 2021 | 91 | 0.160 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 116 | 0.160 |
Why?
|
| Humans | 22 | 2026 | 65140 | 0.150 |
Why?
|
| Male | 14 | 2026 | 31047 | 0.140 |
Why?
|
| Aged | 10 | 2026 | 14965 | 0.140 |
Why?
|
| Ureteral Neoplasms | 1 | 2018 | 10 | 0.140 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 279 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 45 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 1656 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2026 | 373 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 168 | 0.130 |
Why?
|
| Prognosis | 4 | 2022 | 1784 | 0.120 |
Why?
|
| Dasatinib | 1 | 2016 | 7 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 35 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2016 | 64 | 0.120 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2016 | 28 | 0.120 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 94 | 0.120 |
Why?
|
| Biopsy | 3 | 2026 | 456 | 0.110 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 325 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 217 | 0.110 |
Why?
|
| Female | 11 | 2026 | 34018 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 731 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6872 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2023 | 1038 | 0.090 |
Why?
|
| Adult | 6 | 2026 | 17358 | 0.080 |
Why?
|
| Nephrectomy | 2 | 2020 | 92 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 415 | 0.070 |
Why?
|
| Mutation | 1 | 2016 | 2661 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2026 | 5792 | 0.060 |
Why?
|
| Kidney | 2 | 2020 | 451 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2017 | 261 | 0.060 |
Why?
|
| Gastrectomy | 1 | 2026 | 39 | 0.060 |
Why?
|
| Erectile Dysfunction | 1 | 2026 | 28 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 5614 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 1565 | 0.060 |
Why?
|
| Gastric Bypass | 1 | 2026 | 69 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 2483 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 1220 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 2102 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1480 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2620 | 0.050 |
Why?
|
| Administration, Intravesical | 1 | 2023 | 14 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 130 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2022 | 45 | 0.050 |
Why?
|
| Bronchi | 1 | 2022 | 85 | 0.050 |
Why?
|
| Transcriptome | 1 | 2026 | 399 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2023 | 210 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2021 | 129 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2026 | 490 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2023 | 277 | 0.040 |
Why?
|
| Cathepsin L | 1 | 2021 | 21 | 0.040 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2021 | 8 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 29 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 75 | 0.040 |
Why?
|
| Cell Movement | 1 | 2023 | 482 | 0.040 |
Why?
|
| Respiratory System | 1 | 2021 | 46 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 178 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2021 | 199 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 121 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 576 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2023 | 274 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 39 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 67 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 222 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2020 | 297 | 0.040 |
Why?
|
| Transfection | 1 | 2021 | 700 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 302 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 657 | 0.030 |
Why?
|
| Smoking | 1 | 2022 | 862 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 883 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 896 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 64 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1113 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1015 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 333 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 981 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 844 | 0.030 |
Why?
|
| Mice | 2 | 2023 | 11119 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 59 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 966 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 203 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1192 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1163 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 3308 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 21345 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2293 | 0.020 |
Why?
|
| United States | 1 | 2021 | 8093 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4809 | 0.020 |
Why?
|